A well-capitalized Swiss pharma company needed to scout and identify early-stage in-licensing opportunities from the New England and East Coast regions. The company, which had a global team, had been actively scouting for suitable assets for several years.
Therapeutic areas of interest included oncology, autoimmune and novel antibiotics. In cancer, the company was focused on first-in-class molecules (large or small) with sound biology underpinning the target and a clear opportunity to stratify patients based on target expression.
Our business development expert, Rob Johnson identified new opportunities that were not easily identifiable through existing industry pipeline databases (e.g. Medtrack etc.). We supported our client through:
- regular attendance at meetings and conferences in Boston and the surrounding area, which were likely to attract new early-stage biotech companies, including investor meetings and presentations on non-dilutive financing
- reviewing new and recent literature to identify emerging opportunities
- searching online databases and contacting companies that fit the criteria
- outreach and networking with tech transfer offices, our industry contacts, and licensing professionals